Profile of Men with Prostate Cancer Undergoing NaF PET by Indication
| Characteristic | Initial staging (n = 1,024) | Suspected FOM (n = 1,997) | Suspected POM (n = 510) |
| Age (y) | |||
| Median | 73 | 75 | 76 |
| 25%–75% quartile | 69–78 | 70–81 | 70–81 |
| Symptoms, signs, or test results (%) | |||
| None | 61.9 | 15.3 | 13.5 |
| Elevated or rising PSA only | 22.8 | 47.0 | 36.7 |
| Pain only | 6.1 | 17.0 | 23.5 |
| Evidence from other imaging | 5.0 | 6.1 | 5.5 |
| Multiple signs/abnormal imaging | 3.4 | 11.7 | 18.0 |
| Specialty of requesting provider (%) | |||
| Urologist | 61.7 | 38.2 | 16.9 |
| Radiation oncologist | 22.4 | 17.7 | 15.7 |
| Medical oncologist | 14.5 | 37.5 | 61.0 |
| Other | 1.4 | 6.6 | 6.4 |
| Pre-PET summary stage (%) | |||
| No evidence of disease or local only | 56.6 | 22.3 | 6.3 |
| Regional or nodal | 4.3 | 5.3 | 0.8 |
| Single metastasis | 3.8 | 11.1 | 13.7 |
| Multiple metastases | 4.2 | 22.9 | 67.1 |
| Unknown | 31.1 | 38.5 | 12.2 |
| Conventional bone scan would be ordered if NaF PET were unavailable (%) | 91.9 | 87.0 | 87.3 |
| Pre-PET plan (%) | |||
| Imaging | 49.8 | 55.7 | 57.1 |
| Body CT | 24.0 | 22.2 | 20.6 |
| Body MR imaging | 9.0 | 16.0 | 16.9 |
| 18F-FDG PET | 13.2 | 12.0 | 16.1 |
| Other imaging | 3.6 | 5.5 | 3.5 |
| Treatment* | 40.7 | 25.9 | 29.2 |
| Radiotherapy | 34.1 | 13.9 | 8.4 |
| Hormonal therapy | 18.6 | 15.4 | 18.0 |
| Surgery | 11.8 | 1.9 | 0.2 |
| Chemotherapy | 4.9† | 8.5 | 16.1 |
| Radiopharmaceutical therapy | 0.3† | 0.9 | 1.4 |
| Immunotherapy | 1.6† | 5.0‡ | 4.1‡ |
| Bisphosphonates | 3.2 | 7.0 | 11.6 |
| Biopsy | 1.9 | 3.3 | 2.5 |
| Watch/no additional therapy | 7.6 | 15.1 | 11.2 |